Scientists drilling down to the molecular roots of Alzheimer’s disease have encountered a good news/bad news scenario. A major player is a gene called TREM2, mutations of which can substantially raise a person’s risk of the disease. The bad news is that in the early stages of the disease, high-risk TREM2 variants can hobble the immune system’s ability to protect the brain from amyloid beta,…
A long-term study of nearly 3,000 adults, aged 57 to 85, found that those who could not identify at least four out of five common odors were more than twice as likely as those with a normal sense of smell to develop dementia within five years. Although 78 percent of those tested were normal – correctly identifying at least four out of five scents – about 14 percent could name just three out…
Researchers at the Keck School of Medicine of the University of Southern California (USC) are tackling Alzheimer’s disease with a new study that intervenes decades before the disease develops.
Brain scientists from Edinburgh have identified a genetic programme that controls the way our brain changes throughout life. The programme controls how and when brain genes are expressed at different times in a person’s life to perform a range of functions, the study found.
Columbia University Medical Center researchers have found that it may be possible to access memories “lost” to Alzheimer’s disease, if their discoveries about memory loss in mice also apply to people with the disease.
A largely aged population is already a reality in some countries, and this will become a worldwide problem by 2047, when the number of the Earth’s old people is likely to surpass the number of young people.
Patients with Alzheimer's disease (AD) have a larger caudate nucleus, a brain area involved in habits and used to navigate in the environment on an autopilot mode, shows for the first time a Canadian-Norwegian study published in Acta Neurologica Scandinavica. Not good news, you may think. Hold on, this could open new research avenues for AD.
Experts say that one-third of the world’s dementia cases could be prevented by managing lifestyle factors such as hearing loss, hypertension and depression.
The Alzheimer's Association announced the launch of a $20 million U.S. two-year clinical trial to test the ability of a multi-dimensional lifestyle intervention to prevent cognitive decline and dementia in 2,500 older adults with no current cognitive symptoms but who are at increased risk for later cognitive decline. The announcement was made at the 2017 Alzheimer's Association International…
A natural compound in strawberries could help treat age-related mental decline and conditions like Alzheimer’s, a new study found.
Genetics isn’t just for geneticists anymore. With the rise of direct-to-consumer genetic testing companies like 23andMe, anyone can rifle through their genotypes at hundreds of thousands of positions throughout their DNA. However, these new possibilities may have some serious drawbacks, says Alzheimer's-specialized site Alzforum.
Long before symptoms of Alzheimer's disease become apparent to patients and their families, biological changes are occurring within the brain. Amyloid plaques, which are clusters of protein fragments, along with tangles of protein known as tau, form in the brain and grow in number, eventually getting in the way of the brain's ability to function. These biological changes can be detected early in…
New research led by the University of Hertfordshire, may significantly change the understanding of cognitive processes that are most impaired at very early stages of Alzheimer's disease. The findings could potentially be used to detect the condition at an earlier stage and improve diagnostic accuracy, by creating new cognitive tests that are more sensitive to brain pathology than ones currently…
Scientists are hoping that a single drug can treat two devastating brain diseases: Parkinson's and Alzheimer's. The drug is nilotinib, which is approved to treat a form of leukemia.
The brain disease “progressive supranuclear palsy” (PSP) is currently incurable and its symptoms can only be eased to a very limited degree. PSP impairs eye movements, locomotion, balance control, and speech. Scientists at the German Center for Neurodegenerative Diseases (DZNE) and the Technical University of Munich (TUM) have now discovered a molecular mechanism that may help in the search…
Scientists at Washington University School of Medicine in St. Louis have detailed the structure of a molecule that has been implicated in Alzheimer’s disease. Knowing the shape of the molecule — and how that shape may be disrupted by certain genetic mutations — can help in understanding how Alzheimer’s and other neurodegenerative diseases develop and how to prevent and treat them.
Researchers from Columbia University Medical Center (CUMC), New York State Psychiatric Institute, and NewYork-Presbyterian reported that an odor identification test may prove useful in predicting cognitive decline and detecting early-stage Alzheimer’s disease. Their two studies, presented at the Alzheimer’s Association’s International Conference in Toronto, Canada, suggest that the…
The cause of Alzheimer’s disease remains unknown. Early diagnosis is currently not possible as clinical symptoms only occur once a large number of neurones in the brain have already been destroyed. There is no treatment available either.
New EU-funded project CoSTREAM targets the common mechanisms and pathways of stroke, Alzheimer’s disease to improve disease prevention and treatment, by combining clinical, genetic, epidemiologic, metabolic and radiologic research to develop an organ-on-a-chip in vitro model for the blood-brain connection that will revolutionise drug-development.
Georgetown University researchers are reporting the first case of Alzheimer’s disease diagnosed in an HIV-positive individual. The finding in a 71-year-old man triggers a realization about HIV survivors now reaching the age when Alzheimer’s risk begins to escalate.
Neurologists are gaining new insights into dementia imaging by harnessing the latest opportunities offered by Positron Emission Tomography (PET).
An international public-private research consortium has identified and validated a cellular role of a primary Parkinson’s disease drug target, the LRRK2 kinase. This important finding illuminates a novel route for therapeutic development and intervention testing for Parkinson’s, the second most common neurodegenerative disease after Alzheimer’s.
Proteins are like a body’s in-house Lego set. These large, complex molecules are made up of building blocks called amino acids. Most of the time, proteins fold correctly, but sometimes they can misfold. This misfolding causes the proteins to get sticky, and that can promote clumping, or aggregation, which is the hallmark of several neurodegenerative diseases such as ALS, Alzheimer’s and…
More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid.
NIH-funded study highlights the possible role of glial brain cells in neurological disorders.
